Suppr超能文献

胃蛋白酶抑制剂,一种对携带L1210肿瘤的小鼠具有腹水抑制作用的物质。

Pepstatin, an ascites retardant of L1210 tumor-bearing mice.

作者信息

Greenbaum L M, Semente G

出版信息

J Natl Cancer Inst. 1977 Jul;59(1):259-62. doi: 10.1093/jnci/59.1.259.

Abstract

The effect of pepstatin on the kinetics of ascitic fluid accumulation in L1210 tumor-bearing mice (DBA/2) was observed. Following inoculation of 1.5x10(6) tumor cells, untreated mice reached a peak of fluid accumulation on day 6 and remained at this level until death on day 9. A "lag" phase of 4 days occurred before fluid accumulation was seen. Pepstatin administered SC in a single dose of 80 mg/kg during the lag phase, significantly retarded fluid accumulation as compared to untreated animals. Pepstatin administered following fluid accumulation was much less effective. We concluded that pepstatin prevents fluid accumulation rather than acts as a diuretic agent. The term "ascites retardant" is suggested for the pharmacologic actions of pepstatin, since it prevents fluid accumulation without diminishing the cell count.

摘要

观察了胃蛋白酶抑制剂对L1210荷瘤小鼠(DBA/2)腹水形成动力学的影响。接种1.5×10⁶个肿瘤细胞后,未治疗的小鼠在第6天达到腹水积聚高峰,并一直维持在此水平直至第9天死亡。在出现腹水积聚之前有4天的“延迟”期。在延迟期以80mg/kg的单剂量皮下注射胃蛋白酶抑制剂,与未治疗的动物相比,显著延缓了腹水积聚。在腹水积聚后给予胃蛋白酶抑制剂效果要差得多。我们得出结论,胃蛋白酶抑制剂可预防腹水积聚,而不是作为利尿剂起作用。鉴于胃蛋白酶抑制剂可预防液体积聚而不减少细胞计数,建议用“腹水阻滞剂”这一术语来描述其药理作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验